Is Chimerix, Inc. (CMRX) a Buy, Sell, or Hold?
Chimerix, Inc.
NASDAQ:CMRX
$8.54 USD
$0 (0.0%)
- Volume
- 2.55M
- Average Volume
- 4.26M
- Market Capitalization
- $801.08M
- P/E Ratio
- -8.63
- Dividend Yield
- 0.00%
- Price Target
- $8.55
- Year High
- $8.55
- Year Low
- $0.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.70
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael T. Andriole |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CMRX |
| CUSIP | 16934W106 |
| CIK | 0001117480 |
| Web | https://www.chimerix.com |
| Phone | 919 806 1074 |
| Currency | USD |
| Employees | 79 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.70 |
| Quick Ratio | 5.80 |
| Cash Ratio | 1.30 |
Sales & Book Value
| Annual Sales | $212K |
| Price / Sales | 3778.70 |
| Cash Flow | -0.84 |
| Price / Cash Flow | -10.64 |
| Price / Book | 6.30 |
Price Target and Rating
| Average Stock Price Forecast | $8.55 |
| High Stock Price Forecast | $8.55 |
| Low Stock Price Forecast | $8.55 |
| Forecast Upside/Downside | -0.12% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 25 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.99 |
| Trailing P/E Ratio | -8.63 |
| PEG Ratio | 0.81 |
| P/E Growth | 0.81 |
| Net Income | $-88.39M |
| Net Margin | -41691.98% |
| Pretax Margin | -41691.98% |
| Return on Equity | -56.17% |
| Return on Assets | -60.54% |
Financials Score
| AltmanZ Score | 10.02 |
| Piotroski Score | 4.00 |
| Working Capital | 112.08M |
| Total Assets | 146.01M |
| Ebit | -96.57M |
| Market Cap | 801.08M |
| Total Liabilities | 24.33M |
Poll Results
About Chimerix, Inc. (NASDAQ:CMRX) Stock
Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medical countermeasure. Beyond its commercial offering, Chimerix boasts a robust clinical-stage pipeline: ONC201 targets recurrent diffuse midline glioma in patients whose tumors possess the H3 K27M mutation. ONC206, an imipridone, is a Phase I candidate for solid tumors, functioning as both a Dopamine Receptor D2 (DRD2) antagonist and a caseinolytic protease P (ClpP) agonist. Notably, it exhibits superior non-competitive antagonism of DRD2 compared to O ... NC201. ONC212, another imipridone, acts as an agonist for the orphan G protein-coupled receptor (GPCR) tumor suppressor GPR132 and ClpP. This compound is being explored for a range of solid tumors and blood cancers, including pancreatic cancer and leukemias. dociparstat sodium (DSTAT) aims to overcome chemotherapy resistance in acute myeloid leukemia (AML) by inhibiting crucial proteins found in leukemic blasts and stem cells. Chimerix has also forged strategic partnerships, including licensing agreements with: The Biomedical Advanced Research and Development Authority (BARDA) for brincidofovir's smallpox treatment development. Cantex Pharmaceuticals, Inc. for the development and commercialization of a glycosaminoglycan compound. SymBio Pharmaceuticals for the development, manufacturing, and commercialization of BCV (brincidofovir) across multiple human indications. Established in 2000, Chimerix, Inc. maintains its headquarters in Durham, North Carolina.
Frequently Asked Questions
-
What is the current Chimerix, Inc. (CMRX) stock price?
-
Chimerix, Inc.(NASDAQ:CMRX) stock price is $8.54 in the last trading session. During the trading session, CMRX stock reached the peak price of $8.55 while $0.75 was the lowest point it dropped to. The percentage change in CMRX stock occurred in the recent session was 0.0% while the dollar amount for the price change in CMRX stock was $0.
-
CMRX's industry and sector of operation?
-
The NASDAQ listed CMRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CMRX?
-
Thomas J. Riga | Chief Operating & Commercial Officer
Roy W. Ware | Chief Manufacturing & Technology Officer
David Jakeman | Vice President of Accounting & Finance
Michelle LaSpaluto | Chief Financial Officer
Michael T. Andriole | Chief Executive Officer, President & Director -
How many employees does CMRX have?
-
Number of CMRX employees currently stands at 79. CMRX operates from 2505 Meridian Parkway, Durham, NC 27713, US.
-
Link for CMRX official website?
-
Official Website of CMRX is: https://www.chimerix.com
-
How do I contact CMRX?
-
CMRX could be contacted at phone #919 806 1074 and can also be accessed through its website. CMRX operates from 2505 Meridian Parkway, Durham, NC 27713, US.
-
How many shares of CMRX are traded daily?
-
The average number of CMRX shares traded daily for last 3 months was 4.26M.
-
What is the market cap of CMRX currently?
-
The market value of CMRX currently stands at $801.08M with its latest stock price at $8.54